Clifford Chance advises on MicroTech Medical US$249 million Hong Kong IPO

Clifford Chance advises on MicroTech Medical US$249 million Hong Kong IPO

Leading international law firm Clifford Chance has advised the joint sponsors Goldman Sachs and China International Capital Corporation on MicroTech Medical's US$249 million (HK$1.94 billion) initial public offering (IPO) on the mainboard of the Hong Kong Stock Exchange under Chapter 18A of the Listing Rules. The Hangzhou-based firm offers diabetes therapy and manufactures medical devices to improve diabetes management globally. Besides its home country, MicroTech Medical's flagship product - the equal patch insulin pump system (Equil) - is sold to over 20 countries across Europe, Asia Pacific, the Middle East, Africa and Latin America.

The deal was jointly led by partners Fang Liu and Virginia Lee, supported by counsel Chen Sheng, associates Chen Hongzhou, Jiao Luyi, Fan Yumeng and Yang Tao.

Partner Fang Liu commented, "We are very proud to support on the MicroTech Medical's IPO, our third medical device company HK listing since the middle of this year, following Zylox-Tonbridge's in July and Angelalign's in June."